Human papillomavirus and abnormal cervical lesions among HIV-infected women in HIV-discordant couples from Kenya

Objective HIV infection increases the risk of high-grade cervical neoplasia and invasive cervical carcinoma. The study addresses the limited data describing human papillomavirus (HPV) infection and cervical neoplasia among HIV-infected women in HIV-discordant relationships in sub-Saharan Africa, which is needed to inform screening strategies. Methods A cross-sectional study of HIV-infected women with HIV-uninfected partners was conducted to determine the distribution of type-specific HPV infection and cervical cytology. This study was nested in a prospective cohort recruited between September 2007 and December 2009 in Nairobi, Kenya. Cervical cells for HPV DNA testing and conventional cervical cytology were collected. HPV types were detected and genotyped by Roche Linear Array PCR assay. Results Among 283 women, the overall HPV prevalence was 62%, and 132 (47%) had ≥1 high-risk (HR)-HPV genotype. Of 268 women with cervical cytology results, 18 (7%) had high-grade cervical lesions or more severe by cytology, of whom 16 (89%) were HR-HPV-positive compared with 82 (41%) of 199 women with normal cytology (p<0.001). The most common HR-HPV types in women with a high-grade lesion or more severe by cytology were HPV-52 (44%), HPV-31 (22%), HPV-35 (22%), HPV-51 (22%) and HPV-58 (22%). HR-HPV genotypes HPV-16 or HPV-18 were found in 17% of women with high-grade lesions or more severe. HR-HPV screening applied in this population would detect 89% of those with a high-grade lesion or more severe, while 44% of women with normal or low-grade cytology would screen positive. Conclusion HR-HPV prevalence was high in this population of HIV-infected women with an uninfected partner. Choice of screening for all HR genotypes versus a subset of HR genotypes in these HIV-infected women will strongly affect the performance of an HPV screening strategy relative to cytological screening. Regional and subpopulation differences in HR-HPV genotype distributions could affect screening test performance.

[1]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[2]  S. Temin,et al.  Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses , 2018, British Medical Journal.

[3]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[4]  S. Franceschi,et al.  Carcinogenicity of Human Papillomavirus (HPV) Types in HIV-Positive Women: A Meta-Analysis From HPV Infection to Cervical Cancer , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  R. Rossi,et al.  Multiple HPV infections in female sex workers in Western Kenya: implications for prophylactic vaccines within this sub population , 2017, Infectious Agents and Cancer.

[6]  M. Plummer,et al.  Effect of HIV Infection on Human Papillomavirus Types Causing Invasive Cervical Cancer in Africa , 2016, Journal of acquired immune deficiency syndromes.

[7]  Jennifer S. Smith,et al.  Individual and partner risk factors associated with abnormal cervical cytology among women in HIV-discordant relationships , 2014, International journal of STD & AIDS.

[8]  Jennifer S. Smith,et al.  Incidence and progression of cervical lesions in women with HIV: a systematic global review , 2014, International journal of STD & AIDS.

[9]  C. Poole,et al.  High-Risk Human Papillomavirus Messenger RNA Testing in Physician- and Self-Collected Specimens for Cervical Lesion Detection in High-Risk Women, Kenya , 2013, Sexually transmitted diseases.

[10]  N. Kiviat,et al.  Multiple human papillomavirus infections and HIV seropositivity as risk factors for abnormal cervical cytology among female sex workers in Nairobi , 2013, International journal of STD & AIDS.

[11]  M. Hudgens,et al.  Validation of Cervical Cancer Screening Methods in HIV Positive Women from Johannesburg South Africa , 2013, PloS one.

[12]  S. Franceschi,et al.  Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya , 2012, British Journal of Cancer.

[13]  Jennifer S. Smith,et al.  Knowledge and Acceptability of Pap Smears, Self-Sampling and HPV Vaccination among Adult Women in Kenya , 2012, PloS one.

[14]  J. H. van de Wijgert,et al.  Prevalence and Concordance of HPV, HIV, and HSV-2 in Heterosexual Couples in Kigali, Rwanda , 2012, Sexually transmitted diseases.

[15]  D. Constant,et al.  Genital human papillomavirus prevalence and human papillomavirus concordance in heterosexual couples are positively associated with human immunodeficiency virus coinfection. , 2009, The Journal of infectious diseases.

[16]  S. Franceschi,et al.  Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update , 2007, International journal of cancer.

[17]  S. Franceschi,et al.  Human papillomavirus types among women infected with HIV: a meta-analysis , 2006, AIDS.

[18]  P. Schlag,et al.  Enhanced Detection and Typing of Human Papillomavirus (HPV) DNA in Anogenital Samples with PGMY Primers and the Linear Array HPV Genotyping Test , 2006, Journal of Clinical Microbiology.

[19]  B. Estambale,et al.  Impact of HIV infection on invasive cervical cancer in Kenyan women , 2003, AIDS.

[20]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[21]  S. Vansteelandt,et al.  Distribution of Human Papillomavirus in a Family Planning Population in Nairobi, Kenya , 2003, Sexually transmitted diseases.

[22]  M. Plummer,et al.  Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis , 2003, British Journal of Cancer.

[23]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[24]  L. Jagodzinski,et al.  Evaluation of Performance of the Gen-Probe Human Immunodeficiency Virus Type 1 Viral Load Assay Using Primary Subtype A, C, and D Isolates from Kenya , 2000, Journal of Clinical Microbiology.

[25]  David R. Scott,et al.  Improved Amplification of Genital Human Papillomaviruses , 2000, Journal of Clinical Microbiology.

[26]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[27]  L. Kalish,et al.  Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. , 1999, Journal of the National Cancer Institute.

[28]  S. Franceschi,et al.  Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya , 2008, International journal of cancer.

[29]  N. Kiviat,et al.  Genital Human Papillomavirus Infection: Incidence and Risk Factors in a Cohort of Female University Students , 2003 .